Home » Stocks » GTBP

GT Biopharma, Inc (GTBP)

Stock Price: $0.4700 USD 0.0100 (2.17%)
Updated Jan 27, 2021 3:35 PM EST - Market open
Market Cap 39.34M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 90.95M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $0.4700
Previous Close $0.4600
Change ($) 0.0100
Change (%) 2.17%
Day's Open 0.4850
Day's Range 0.4500 - 0.4850
Day's Volume 544,799
52-Week Range 0.083 - 0.77

News

Hide News
  • All
  • Videos
  • Press Releases
PRNewsWire - 1 week ago

BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK...

PRNewsWire - 4 weeks ago

BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK...

PRNewsWire - 1 month ago

BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK ...

PRNewsWire - 1 month ago

BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK ce...

PRNewsWire - 1 month ago

BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK...

InvestorPlace - 2 months ago

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...

Other stocks mentioned: CANF, FPRX, IFRX, TNXP, VTVT, VXRT
InvestorPlace - 10 months ago

GT Biopharma (GTBP) news for Tuesday about it working on a possible treatment for the coronavirus from China has GTBP stock heading higher.

About GTBP

GT Biopharma, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase... [Read more...]

Industry
Biotechnology
Founded
1965
CEO
Anthony Cataldo
Employees
2
Stock Exchange
OTCMKTS
Ticker Symbol
GTBP
Full Company Profile